Computer-aided dosage in oral anticoagulation therapy using phenprocoumon: Problems and approaches

Hamostaseologie

Volumn 30, Issue 4, 2010, Pages 183-189

  Cromme, Ludwig J ^a   Voller H ^b   Gabler F ^a   Salzwedel, A ^b   Taborski, U ^c  

^a BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^b Rehabilitationszentrum für Innere Medizin   (Germany)

^c Deutsche Gesellschaft für Humanplasma   (Germany)

Author keywords

Computer aided expert system; Dosage; Mathematical models in anticoagulation therapy; Oral anticoagulation; Phenprocoumon

Indexed keywords

PHENPROCOUMON;

ANTICOAGULATION; COMPUTER AIDED DESIGN; HUMAN; INTERNATIONAL NORMALIZED RATIO; MATHEMATICAL MODEL; REVIEW; THROMBOEMBOLISM;

EID: 78649991390     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619051     Document Type: Review

References (15)

1. Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Int Med 1994; 154: 1443-1448.
2. Anand S, Yusuf S, Xie C et al. Oral Anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227.
3. Bergert F W, Braun M, Conrad D et al. Hausärztliche Leitlinie Antikoagulation mit Vitamin-K-Antagonisten. Version 1.02 vom 10.01.2007. www.pmvforschungsgruppe.de/pdf/03-publikationen/antikoagulation-ll.pdf.
4. Berthold W, Miller Th, Walther-Berthold St. Dosisanpassung bei Vitamin-K-Antagonisten; Offene Pilotstudie. Phlebologie 2005; 34: 30-33.
5. Cromme L. A linear model for long-term dosage of anticoagulant drugs. PAMM 2003, 3/1: 462-463.
6. Fahlberg-List. HEXAL AG. Fachinformation Falithrom 1995.
7. Goldinger A. Antikoagulanzien. 1998. www.staff. uni-mainz.de/ goldinge/cumarine.htm.
8. Haustein KO, Richter M, Vogel G. Zur Optimierung einer Langzeitbehandlung mit Phenprocoumon. Dt Gesundh-Wesen 1975, 30: 1514-1522.
9. Manotti C, Moia M, Palareti G et al. Effect of computer- aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment). Haema tologica 2001, 86: 1060-1070.
10. Mohler E R. Atherothrombosis - Wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med 2007; 357: 293-296.
11. Neeser K, Erny-Albrecht K, Völler H, Weber C. Antikoagulation mit oralen Vitamin-K-Antagonisten bei Risikopatienten: klinischer und wirtschaftlicher Nutzen einer adäquaten Prävention. Journal für Kardiologie 2006; 13: 313-320.
12. Pasterkamp E, Kruithof CJ, Van der Meer FJ et al. A model-based algorithm for the monitoring of longterm anticoagulation therapy. J Thromb Haemost 2005; 3: 915-921. (Pubitemid 41632819)
13. Semin A M. Developmental hemostasis: relevance to hemostatic problems during childhood. Thromb Haemost 1995; 21: 341-356.
14. Torn M, Bollen WL, Van der Meer FJ et al. Risks of oral anticoagulant therapy with increasing age. Arch Int Med 2005; 165: 1527-1532. (Pubitemid 41058034)
15. Ufer M, Kammerer B, Kirchheiner J et al. Determination of phenprocoumon, warfarin, and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 809: 217-226.